Ruden Brian 4

4 · Medicine Man Technologies, Inc. · Filed Apr 30, 2021

Insider Transaction Report

Form 4

Period: 2020-10-01

Medicine Man Technologies, Inc.SHWZ

Ruden Brian

Director

Transactions

Award
Series A Cumulative Convertible Preferred Stock
2020-12-18$1000.00/sh+1,370$1,370,000→ 2,801 total
Exercise: $1.20→ Common Stock (1,141,667 underlying)
Award
Series A Cumulative Convertible Preferred Stock
2021-03-02$1000.00/sh+5,746$5,746,000→ 9,151 total
Exercise: $1.20→ Common Stock (4,788,333 underlying)
Award
Warrant (Right to Buy)
2020-12-17+268,375→ 268,375 total
Exercise: $1.20From: 2020-12-17Exp: 2025-12-17→ Common Stock (268,375 underlying)
Award
Warrant (Right to Buy)
2021-02-03+113,211→ 113,211 total
Exercise: $1.20From: 2021-02-03Exp: 2026-02-03→ Common Stock (113,211 underlying)
Award
Common Stock
2020-10-01+42,735→ 42,735 total
Award
Series A Cumulative Convertible Preferred Stock
2020-12-17$1000.00/sh+1,431$1,431,000→ 1,431 total
Exercise: $1.20→ Common Stock (1,192,500 underlying)
Award
Series A Cumulative Convertible Preferred Stock
2021-02-03$1000.00/sh+604$604,000→ 3,405 total
Exercise: $1.20→ Common Stock (503,333 underlying)
Award
Warrant (Right to Buy)
2020-12-18+257,036→ 257,036 total
Exercise: $1.20From: 2020-12-18Exp: 2025-12-18→ Common Stock (257,036 underlying)
Award
Warrant (Right to Buy)
2021-03-02+1,077,331→ 1,077,331 total
Exercise: $1.20From: 2021-03-02Exp: 2026-03-02→ Common Stock (1,077,331 underlying)

Footnotes (5)

[F1]The issuer granted the reporting person shares of common stock with an aggregate value of $50,000 for service on its board of directors.
[F2]Subject to adjustment, as described in the Certificate of Designation.
[F3]The shares of Series A Cumulative Convertible Preferred Stock (the "Series A Preferred Shares") are convertible into shares of the common stock (the "Common Shares") of Medicine Man Technologies, Inc. (the "Company") upon the events specified in the Company's Certificate of Designation of Series A Cumulative Convertible Preferred Stock (the "Certificate of Designation"). The Preferred stock is perpetual and therefore has no expiration date.
[F4]Represents the number of Common Shares issuable upon conversion of the Series A Preferred Shares on the date of the reported transaction. Each Series A Preferred Share is convertible into that number of Common Shares equal to the preference amount (initially $1,000) plus any accrued dividends with respect to such share, divided by the conversion price (initially $1.20), subject to adjustment as set forth in the Certificate of Designation. The Series A Preferred Shares earn a cumulative dividend of 8% per annum.
[F5]The reporting person received the warrants under Asset Purchase Agreements entered into by entities partly-owned by the reporting person upon the sale of assets by such entities to the issuer on the following dates, December 17, 2020; December 18, 2020; February 3, 2021; March 2, 2021. The consideration paid for the assets consisted of a mix of cash, deferred cash, shares of the issuer's Series A Cumulative Convertible Preferred Stock (the "Series A Shares") and warrants to purchase shares of the issuer's common stock

Documents

1 file

4
ownership.xmlPrimary